

Chaim Putterman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3929962/publications.pdf>

Version: 2024-02-01

163
papers

8,730
citations

36271

51
h-index

53190

85
g-index

171
all docs

171
docs citations

171
times ranked

7829
citing authors

#	ARTICLE	IF	CITATIONS
1	Membrane attack complex (MAC) deposition in renal tubules is associated with interstitial fibrosis and tubular atrophy: a pilot study. <i>Lupus Science and Medicine</i> , 2022, 9, e000576.	1.1	7
2	The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	25
3	High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. <i>Rheumatology</i> , 2022, 61, 4335-4343.	0.9	6
4	<sc>Aptamer-Based</sc> Screen of Neuropsychiatric Lupus Cerebrospinal Fluid Reveals Potential Biomarkers That Overlap With the Choroid Plexus Transcriptome. <i>Arthritis and Rheumatology</i> , 2022, 74, 1223-1234.	2.9	6
5	Cognitive Impairment in Anti-Phospholipid Syndrome and Anti-Phospholipid Antibody Carriers. <i>Brain Sciences</i> , 2022, 12, 222.	1.1	2
6	Urine Proteomics and Renal <sc>Single-Cell</sc> Transcriptomics Implicate Interleukin-16 in Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 829-839.	2.9	38
7	Choroid Plexus-Infiltrating T Cells as Drivers of Murine Neuropsychiatric Lupus. <i>Arthritis and Rheumatology</i> , 2022, 74, 1796-1807.	2.9	7
8	BTK inhibition modulates multiple immune cell populations involved in the pathogenesis of immune mediated nephritis. <i>Clinical Immunology</i> , 2021, 223, 108640.	1.4	1
9	Neurofilament light is a biomarker of brain involvement in lupus and primary Sjögren's syndrome. <i>Journal of Neurology</i> , 2021, 268, 1385-1394.	1.8	18
10	Remodeling of Neurotransmission, Chemokine, and PI3K-AKT Signaling Genomic Fabrics in Neuropsychiatric Systemic Lupus Erythematosus. <i>Genes</i> , 2021, 12, 251.	1.0	8
11	A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus. <i>ACR Open Rheumatology</i> , 2021, 3, 116-123.	0.9	5
12	Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic versus regulatory immune cell subsets. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1281-1292.	1.5	57
13	Promise and complexity of lupus mouse models. <i>Nature Immunology</i> , 2021, 22, 683-686.	7.0	5
14	TWEAKing the Hippocampus: The Effects of TWEAK on the Genomic Fabric of the Hippocampus in a Neuropsychiatric Lupus Mouse Model. <i>Genes</i> , 2021, 12, 1172.	1.0	5
15	3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine. <i>Nature Communications</i> , 2021, 12, 4447.	5.8	30
16	Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. <i>Lupus Science and Medicine</i> , 2021, 8, e000522.	1.1	5
17	CXCL13 Neutralization Attenuates Neuropsychiatric Manifestations in Lupus-Prone Mice. <i>Frontiers in Immunology</i> , 2021, 12, 763065.	2.2	6
18	Development of Murine Systemic Lupus Erythematosus in the Absence of BAFF. <i>Arthritis and Rheumatology</i> , 2020, 72, 292-302.	2.9	6

#	ARTICLE	IF	CITATIONS
19	Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. <i>Arthritis Care and Research</i> , 2020, 72, 233-242.	1.5	17
20	Advances in the diagnosis, pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2020, 32, 152-158.	2.0	33
21	4336 Renal Tubular Complement C9 Deposition is Associated with Renal Tubular Damage and Fibrosis in Lupus Nephritis. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 144-144.	0.3	0
22	Quantitative planar array screen of 1000 proteins uncovers novel urinary protein biomarkers of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1349-1361.	0.5	39
23	The T Cell Receptor Repertoire in Neuropsychiatric Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2020, 11, 1476.	2.2	8
24	Age-associated changes in the circulating human antibody repertoire are upregulated in autoimmunity. <i>Immunity and Ageing</i> , 2020, 17, 28.	1.8	16
25	Phoenix from the flames: Rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis. <i>Autoimmunity Reviews</i> , 2020, 19, 102668.	2.5	35
26	MO007A PHASE 1B MULTIPLE ASCENDING-DOSE STUDY OF A CD6 TARGETED THERAPY, ITOLIZUMAB, IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WITH OR WITHOUT ACTIVE PROLIFERATIVE LUPUS NEPHRITIS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
27	Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities. <i>Nature Communications</i> , 2020, 11, 2197.	5.8	55
28	Are lupus animal models useful for understanding and developing new therapies for human SLE?. <i>Journal of Autoimmunity</i> , 2020, 112, 102490.	3.0	13
29	Upregulation of Proinflammatory Bradykinin Peptides in Systemic Lupus Erythematosus and Rheumatoid Arthritis. <i>Journal of Immunology</i> , 2020, 205, 369-376.	0.4	8
30	A Novel Microglia-Specific Transcriptional Signature Correlates With Behavioral Deficits in Neuropsychiatric Lupus. <i>Frontiers in Immunology</i> , 2020, 11, 230.	2.2	27
31	Cell-bound complement activation products associate with lupus severity in SLE. <i>Lupus Science and Medicine</i> , 2020, 7, e000377.	1.1	7
32	Cognitive dysfunction in autoimmune rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2020, 22, 78.	1.6	28
33	Single Cell RNA Sequencing in Human Disease: Renal, Pancreatic, and Viral Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1255, 195-202.	0.8	2
34	The Incidence and Prevalence of Adult Primary Sjögren's Syndrome in New York County. <i>Arthritis Care and Research</i> , 2019, 71, 949-960.	1.5	38
35	Methodological considerations in comparing access to Pre-emptive renal transplantation between SLE and other ESRD causes in the USRDS. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 678-685.	1.6	2
36	Single-cell RNA sequencing for the study of lupus nephritis. <i>Lupus Science and Medicine</i> , 2019, 6, e000329.	1.1	6

#	ARTICLE	IF	CITATIONS
37	Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program. <i>Lupus Science and Medicine</i> , 2019, 6, e000344.	1.1	22
38	Anti-IFNAR treatment does not reverse neuropsychiatric disease in MRL/lpr lupus mice. <i>Lupus</i> , 2019, 28, 1510-1523.	0.8	10
39	The immune cell landscape in kidneys of patients with lupus nephritis. <i>Nature Immunology</i> , 2019, 20, 902-914.	7.0	501
40	Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice. <i>Lupus Science and Medicine</i> , 2019, 6, e000313.	1.1	3
41	Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. <i>Nature Immunology</i> , 2019, 20, 915-927.	7.0	275
42	Lipocalin-2 is a pathogenic determinant and biomarker of neuropsychiatric lupus. <i>Journal of Autoimmunity</i> , 2019, 96, 59-73.	3.0	43
43	Pathogenesis of Neuropsychiatric Lupus. , 2019, , 317-323.		0
44	A Markov Multi-State model of lupus nephritis urine biomarker panel dynamics in children: Predicting changes in disease activity. <i>Clinical Immunology</i> , 2019, 198, 71-78.	1.4	12
45	Neuropsychiatric lupus: new mechanistic insights and future treatment directions. <i>Nature Reviews Rheumatology</i> , 2019, 15, 137-152.	3.5	228
46	NF- κ B signaling in myeloid cells mediates the pathogenesis of immune-mediated nephritis. <i>Journal of Autoimmunity</i> , 2019, 98, 33-43.	3.0	22
47	Tertiary lymphoid structures in the choroid plexus in neuropsychiatric lupus. <i>JCI Insight</i> , 2019, 4, .	2.3	50
48	PD-1hiCXCR5 ⁺ T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. <i>JCI Insight</i> , 2019, 4, .	2.3	171
49	Mechanisms of neuropsychiatric lupus: The relative roles of the blood-cerebrospinal fluid barrier versus blood-brain barrier. <i>Journal of Autoimmunity</i> , 2018, 91, 34-44.	3.0	50
50	Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: A retrospective cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 545-551.	1.6	47
51	The blood-brain barrier, TWEAK, and neuropsychiatric involvement in human systemic lupus erythematosus and primary Sjögren's syndrome. <i>Lupus</i> , 2018, 27, 2101-2111.	0.8	8
52	Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Sphingosine-1-Phosphate Signaling. <i>Frontiers in Immunology</i> , 2018, 9, 2189.	2.2	44
53	BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis. <i>Clinical Immunology</i> , 2018, 197, 205-218.	1.4	39
54	Structure-Function in Antibodies to Double-Stranded DNA. , 2018, , 127-144.		0

#	ARTICLE	IF	CITATIONS
55	Brief Report: Tubulointerstitial Damage in Lupus Nephritis: A Comparison of the Factors Associated With Tubulointerstitial Inflammation and Renal Scarring. <i>Arthritis and Rheumatology</i> , 2018, 70, 1801-1806.	2.9	34
56	A Distinct T Follicular Helper Cell Subset Infiltrates the Brain in Murine Neuropsychiatric Lupus. <i>Frontiers in Immunology</i> , 2018, 9, 487.	2.2	29
57	Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus. <i>Arthritis Research and Therapy</i> , 2018, 20, 10.	1.6	37
58	The SLE-key test serological signature: new insights into the course of lupus. <i>Rheumatology</i> , 2018, 57, 1632-1640.	0.9	9
59	Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. <i>Lupus Science and Medicine</i> , 2018, 5, e000263.	1.1	18
60	OPO217...A permeable blood-brain barrier is not required for neuropsychiatric manifestations in sle and pss., 2018, , .		0
61	New Roadmap for the Journey From Internist to Rheumatologist. <i>Arthritis Care and Research</i> , 2017, 69, 769-775.	1.5	9
62	The blood brain barrier and neuropsychiatric lupus: new perspectives in light of advances in understanding the neuroimmune interface. <i>Autoimmunity Reviews</i> , 2017, 16, 612-619.	2.5	60
63	TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 420-424.	0.6	5
64	Novelties in the field of autoimmunity " 1st Saint Petersburg congress of autoimmunity, the bridge between east and west. <i>Autoimmunity Reviews</i> , 2017, 16, 1175-1184.	2.5	17
65	The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program. <i>Arthritis and Rheumatology</i> , 2017, 69, 2006-2017.	2.9	126
66	Lupus Nephritis: Persistent Challenges, New Approaches. <i>Clinical Immunology</i> , 2017, 185, 1-2.	1.4	3
67	Diagnostic and prognostic tests in systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 351-363.	1.4	27
68	CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus. <i>Clinical Immunology</i> , 2017, 185, 100-108.	1.4	73
69	International validation of a urinary biomarker panel for identification of active lupus nephritis in children. <i>Pediatric Nephrology</i> , 2017, 32, 283-295.	0.9	46
70	Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis. <i>JCI Insight</i> , 2017, 2, .	2.3	164
71	THU0317...Tubulointerstitial Damage Is An Independent Predictor of End Stage Renal Disease in Lupus Nephritis Patients with Mild To Moderate Renal Impairment. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 302.1-302.	0.5	1
72	<sc>F</sc>n14 deficiency protects lupus-prone mice from histological lupus erythematosus-like skin inflammation induced by ultraviolet light. <i>Experimental Dermatology</i> , 2016, 25, 969-976.	1.4	16

#	ARTICLE	IF	CITATIONS
73	What Is a Rheumatologist and How Do We Make One?. <i>Arthritis Care and Research</i> , 2016, 68, 1166-1172.	1.5	24
74	Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton's Tyrosine Kinase. <i>Scientific Reports</i> , 2016, 6, 26164.	1.6	32
75	Urinary high-mobility group box-1 associates specifically with lupus nephritis class V. <i>Lupus</i> , 2016, 25, 1551-1557.	0.8	22
76	ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap. <i>Kidney International Reports</i> , 2016, 1, 327-339.	0.4	1
77	The role of B cells and autoantibodies in neuropsychiatric lupus. <i>Autoimmunity Reviews</i> , 2016, 15, 890-895.	2.5	32
78	AB0435—Immunosignature Technology Identifies Systemic Lupus Erythematosus from A Drop of Serum. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1056.1-1056.	0.5	1
79	A peptide mimic blocks the cross-reaction of anti-DNA antibodies with glomerular antigens. <i>Clinical and Experimental Immunology</i> , 2016, 183, 369-379.	1.1	14
80	B cell and/or autoantibody deficiency do not prevent neuropsychiatric disease in murine systemic lupus erythematosus. <i>Journal of Neuroinflammation</i> , 2016, 13, 73.	3.1	27
81	Intracerebroventricular administration of TNF-like weak inducer of apoptosis induces depression-like behavior and cognitive dysfunction in non-autoimmune mice. <i>Brain, Behavior, and Immunity</i> , 2016, 54, 27-37.	2.0	42
82	Anti-DNA antibody mediated catalysis is isotype dependent. <i>Molecular Immunology</i> , 2016, 69, 33-43.	1.0	12
83	SLE-key [®] rule-out serologic test for excluding the diagnosis of systemic lupus erythematosus: Developing the ImmunArray iCHIP [®] . <i>Journal of Immunological Methods</i> , 2016, 429, 1-6.	0.6	18
84	Insulin-Like Growth Factor Binding Protein-4 as a Marker of Chronic Lupus Nephritis. <i>PLoS ONE</i> , 2016, 11, e0151491.	1.1	11
85	Extracellular RNAs: development as biomarkers of human disease. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 27495.	5.5	72
86	Neuropsychiatric systemic lupus erythematosus persists despite attenuation of systemic disease in MRL/lpr mice. <i>Journal of Neuroinflammation</i> , 2015, 12, 205.	3.1	47
87	Differential Development of Systemic Lupus Erythematosus in NZM 2328 Mice Deficient in Discrete Pairs of BAFF Receptors. <i>Arthritis and Rheumatology</i> , 2015, 67, 2523-2535.	2.9	21
88	B7x/B7-H4 modulates the adaptive immune response and ameliorates renal injury in antibody-mediated nephritis. <i>Clinical and Experimental Immunology</i> , 2015, 179, 329-343.	1.1	14
89	Macrophage depletion ameliorates nephritis induced by pathogenic antibodies. <i>Journal of Autoimmunity</i> , 2015, 57, 42-52.	3.0	74
90	Biomarkers for kidney involvement in pediatric lupus. <i>Biomarkers in Medicine</i> , 2015, 9, 529-543.	0.6	20

#	ARTICLE	IF	CITATIONS
91	Anti-alpha-actinin antibodies are part of the anti-cell membrane antibody spectrum that characterize patients with lupus nephritis. <i>Journal of Autoimmunity</i> , 2015, 61, 54-61.	3.0	23
92	Biomarkers for CNS involvement in pediatric lupus. <i>Biomarkers in Medicine</i> , 2015, 9, 545-558.	0.6	12
93	TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice. <i>Journal of Autoimmunity</i> , 2015, 60, 40-50.	3.0	92
94	Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. <i>Nature Reviews Nephrology</i> , 2015, 11, 329-341.	4.1	289
95	TWEAK/Fn14 Signaling Involvement in the Pathogenesis of Cutaneous Disease in the MRL/lpr Model of Spontaneous Lupus. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1986-1995.	0.3	52
96	The Role of Anti-DNA Antibodies in the Development of Lupus Nephritis: A Complementary, or Alternative, Viewpoint?. <i>Seminars in Nephrology</i> , 2015, 35, 439-443.	0.6	29
97	Deficiency of Fibroblast Growth Factor-Inducible 14 (Fn14) Preserves the Filtration Barrier and Ameliorates Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1053-1070.	3.0	86
98	Therapeutic targeting of macrophages in lupus nephritis. <i>Discovery Medicine</i> , 2015, 20, 43-9.	0.5	40
99	Increased Education is Associated with Decreased Compliance in an Urban Multi-Ethnic Lupus Cohort. <i>Journal of Clinical & Cellular Immunology</i> , 2014, 05, .	1.5	6
100	TWEAK and the progression of renal disease: clinical translation. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, i54-i62.	0.4	94
101	The pathogenesis, diagnosis and treatment of lupus nephritis. <i>Current Opinion in Rheumatology</i> , 2014, 26, 502-509.	2.0	103
102	Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. <i>Lupus Science and Medicine</i> , 2014, 1, e000056.	1.1	65
103	Serum autoantibodies in pristane induced lupus are regulated by neutrophil gelatinase associated lipocalin. <i>Clinical Immunology</i> , 2014, 154, 49-65.	1.4	16
104	TWEAK/Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier. <i>Journal of Neuroinflammation</i> , 2013, 10, 9.	3.1	56
105	Improving Outcomes in Patients with Lupus and End-stage Renal Disease. <i>Seminars in Dialysis</i> , 2013, 26, 590-596.	0.7	21
106	Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway. <i>Journal of Autoimmunity</i> , 2013, 43, 44-54.	3.0	96
107	The constant region affects antigen binding of antibodies to DNA by altering secondary structure. <i>Molecular Immunology</i> , 2013, 56, 28-37.	1.0	31
108	Neuropsychiatric Lupus, the Blood Brain Barrier, and the TWEAK/Fn14 Pathway. <i>Frontiers in Immunology</i> , 2013, 4, 484.	2.2	80

#	ARTICLE	IF	CITATIONS
109	Measurement of cellâ€bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 4040-4047.	6.7	66
110	Role of TWEAK in lupus nephritis: A bench-to-bedside review. <i>Journal of Autoimmunity</i> , 2012, 39, 130-142.	3.0	110
111	The constant region contributes to the antigenic specificity and renal pathogenicity of murine anti-DNA antibodies. <i>Journal of Autoimmunity</i> , 2012, 39, 398-411.	3.0	46
112	Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. <i>Clinical Immunology</i> , 2012, 145, 108-121.	1.4	84
113	Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis. <i>Arthritis Research and Therapy</i> , 2012, 14, R164.	1.6	85
114	Metabolic Disturbances Associated with Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2012, 7, e37210.	1.1	160
115	Neutrophil gelatinaseâ€associated lipocalin is instrumental in the pathogenesis of antibodyâ€mediated nephritis in mice. <i>Arthritis and Rheumatism</i> , 2012, 64, 1620-1631.	6.7	37
116	Autoantibodies in lupus: Culprits or passive bystanders?. <i>Autoimmunity Reviews</i> , 2012, 11, 596-603.	2.5	95
117	IgG3 deficiency extends lifespan and attenuates progression of glomerulonephritis in MRL/lpr mice. <i>Biology Direct</i> , 2012, 7, 3.	1.9	29
118	Neuropsychiatric Symptoms in Lupus. <i>Psychiatric Annals</i> , 2012, 42, 322-328.	0.1	18
119	A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine. <i>Clinical Rheumatology</i> , 2011, 30, 1385-1392.	1.0	74
120	Urinary Biomarkers in Lupus Nephritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2011, 40, 138-150.	2.9	110
121	Modifiable predictors of racial differences in gait velocity in an elderly urban cohort. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A93-A93.	0.5	0
122	The MRL/lpr Mouse Strain as a Model for Neuropsychiatric Systemic Lupus Erythematosus. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-15.	3.0	77
123	Sex and autoantibody titers determine the development of neuropsychiatric manifestations in lupus-prone mice. <i>Journal of Neuroimmunology</i> , 2010, 229, 112-122.	1.1	37
124	Proliferative Glomerulonephritis in Lupus Patients With Human Immunodeficiency Virus Infection: A Difficult Clinical Challenge. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 40, 201-209.	1.6	17
125	Urine Proteome Scans Uncover Total Urinary Protease, Prostaglandin D Synthase, Serum Amyloid P, and Superoxide Dismutase as Potential Markers of Lupus Nephritis. <i>Journal of Immunology</i> , 2010, 184, 2183-2193.	0.4	39
126	Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. <i>Rheumatology</i> , 2010, 49, 960-971.	0.9	94

#	ARTICLE	IF	CITATIONS
127	Deficiency of Type I IFN Receptor in Lupus-Prone New Zealand Mixed 2328 Mice Decreases Dendritic Cell Numbers and Activation and Protects from Disease. <i>Journal of Immunology</i> , 2009, 183, 6021-6029.	0.4	122
128	Depression is an early disease manifestation in lupus-prone MRL/lpr mice. <i>Journal of Neuroimmunology</i> , 2009, 207, 45-56.	1.1	78
129	TWEAK stimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis. <i>Immunology Letters</i> , 2009, 125, 119-128.	1.1	38
130	TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. <i>Cytokine</i> , 2009, 46, 24-35.	1.4	112
131	The role of anti- α -actinin antibodies in the pathogenesis and monitoring of lupus nephritis. <i>Arthritis Research and Therapy</i> , 2009, 11, 137.	1.6	6
132	Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. <i>Arthritis Research and Therapy</i> , 2009, 11, R143.	1.6	156
133	Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: Involvement of HMGB1 in anti-DNA antibody-induced renal injury. <i>Immunology Letters</i> , 2008, 121, 61-73.	1.1	72
134	The novel role of neutrophil gelatinase-B associated lipocalin (NGAL)/Lipocalin-2 as a biomarker for lupus nephritis. <i>Autoimmunity Reviews</i> , 2008, 7, 229-234.	2.5	48
135	Treatment of lupus nephritis: facing the era of immunotherapy. <i>Panminerva Medica</i> , 2008, 50, 235-45.	0.2	13
136	Elevated Urinary VCAM-1, P-Selectin, Soluble TNF Receptor-1, and CXC Chemokine Ligand 16 in Multiple Murine Lupus Strains and Human Lupus Nephritis. <i>Journal of Immunology</i> , 2007, 179, 7166-7175.	0.4	148
137	α -Actinin Immunization Elicits Anti-Chromatin Autoimmunity in Nonautoimmune Mice. <i>Journal of Immunology</i> , 2007, 179, 1313-1321.	0.4	40
138	TWEAK/Fn14 Interactions Are Instrumental in the Pathogenesis of Nephritis in the Chronic Graft-versus-Host Model of Systemic Lupus erythematosus. <i>Journal of Immunology</i> , 2007, 179, 7949-7958.	0.4	140
139	Excreted urinary mediators in an animal model of experimental immune nephritis with potential pathogenic significance. <i>Arthritis and Rheumatism</i> , 2007, 56, 949-959.	6.7	43
140	Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 1894-1903.	6.7	117
141	Anti-alpha-actinin antibodies: A new marker of lupus nephritis. <i>Autoimmunity Reviews</i> , 2007, 6, 464-468.	2.5	39
142	Lipocalin-2, TWEAK, and Other Cytokines as Urinary Biomarkers for Lupus Nephritis. <i>Annals of the New York Academy of Sciences</i> , 2007, 1109, 265-274.	1.8	57
143	Urinary TWEAK and the activity of lupus nephritis. <i>Journal of Autoimmunity</i> , 2006, 27, 242-250.	3.0	119
144	Nephritogenic Anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells. <i>Arthritis and Rheumatism</i> , 2006, 54, 2198-2210.	6.7	70

#	ARTICLE	IF	CITATIONS
145	Association of Î±-actininâ€“binding antiâ€“double-stranded DNA antibodies with lupus nephritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 2523-2532.	6.7	65
146	Differential Binding of Cross-Reactive Anti-DNA Antibodies to Mesangial Cells: The Role of Î±-Actinin. <i>Journal of Immunology</i> , 2006, 176, 7704-7714.	0.4	38
147	Proinflammatory Effects of Tweak/Fn14 Interactions in Glomerular Mesangial Cells. <i>Journal of Immunology</i> , 2006, 176, 1889-1898.	0.4	155
148	Mimotopes for lupus-derived anti-DNA and nucleosome-specific autoantibodies selected from random peptide phage display libraries: facts and follies. <i>Journal of Immunological Methods</i> , 2005, 296, 83-93.	0.6	26
149	Cross-reactivity of human lupus anti-DNA antibodies with Î±-actinin and nephritogenic potential. <i>Arthritis and Rheumatism</i> , 2005, 52, 522-530.	6.7	105
150	BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005, 52, 2080-2091.	6.7	110
151	Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. <i>Journal of Clinical Investigation</i> , 2005, 115, 3428-3439.	3.9	219
152	The role of TWEAK/Fn14 IN the pathogenesis of inflammation and systemic autoimmunity. <i>Frontiers in Bioscience - Landmark</i> , 2004, 9, 2273.	3.0	98
153	New approaches to the renal pathogenicity of anti-DNA antibodies in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2004, 3, 7-11.	2.5	47
154	Î±-Actinin Is a Cross-Reactive Renal Target for Pathogenic Anti-DNA Antibodies. <i>Journal of Immunology</i> , 2002, 168, 3072-3078.	0.4	187
155	A Peptide DNA Surrogate Accelerates Autoimmune Manifestations and Nephritis in Lupus-Prone Mice. <i>Journal of Immunology</i> , 2002, 168, 3617-3626.	0.4	28
156	Antigenic triggers and molecular targets for anti-double-stranded DNA antibodies. <i>Lupus</i> , 2002, 11, 865-871.	0.8	40
157	Orbital mucosa-associated lymphoid tissue (MALT)-type lymphoma in a patient with relapsing polychondritis. <i>Arthritis and Rheumatism</i> , 2001, 44, 1713-1715.	6.7	27
158	OP0071â€“...A pathogenic anti-dna antibody binds to alpha-actinin in renal mesangial cells. , 2001, , .		0
159	Molecular Analysis of the Autoantibody Response in Peptide-Induced Autoimmunity. <i>Journal of Immunology</i> , 2000, 164, 2542-2549.	0.4	59
160	Immunization with a Peptide Surrogate for Double-stranded DNA (dsDNA) Induces Autoantibody Production and Renal Immunoglobulin Deposition. <i>Journal of Experimental Medicine</i> , 1998, 188, 29-38.	4.2	184
161	Studies on the Structure, Regulation, and Pathogenic Potential of Anti-dsDNA Antibodies. <i>Methods</i> , 1997, 11, 70-78.	1.9	33
162	Peptide inhibition of glomerular deposition of an anti-DNA antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 1955-1960.	3.3	190

#	ARTICLE	IF	CITATIONS
163	The double edged sword of the immune response: mutational analysis of a murine anti-pneumococcal, anti-DNA antibody.. Journal of Clinical Investigation, 1996, 97, 2251-2259.	3.9	57